Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors
Authors:
- 1 December 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (12) , 5288-5297
Abstract
In order to assess the natural variation in susceptibility to hepatitis C virus (HCV) NS3 protease inhibitors (PIs) among untreated HCV patient samples, the susceptibilities of 39 baseline clinical isolates were determined using a transient-replication assay on a panel of HCV PIs, including two α-ketoamides (VX-950 and SCH-503034) and three macrocyclic inhibitors (MK-7009, ITMN-191, and TMC-435350). Some natural variation in susceptibility to all HCV PIs tested was observed among the baseline clinical isolates. The susceptibility to VX-950 correlated strongly with the susceptibility to SCH-503034. A moderate correlation was observed between the susceptibilities to ITMN-191 and MK-7009. In contrast, the phenotypic correlations between the α-ketoamides and macrocyclic inhibitors were significantly lower. This difference is partly attributable to reduced susceptibility of the HCV variants containing the NS3 polymorphism Q80K (existing in 47% of genotype 1a isolates) to the macrocyclic compounds but no change in the sensitivity of the same variants to the α-ketoamides tested. Our results suggest that the natural variation in baseline susceptibility may contribute to different degrees of antiviral response among patients in vivo , particularly at lower doses.Keywords
This publication has 32 references indexed in Scilit:
- Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease TargetAngewandte Chemie International Edition, 2010
- MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A ProteaseAntimicrobial Agents and Chemotherapy, 2010
- Natural Variability of NS3 Protease in Patients Infected with Genotype 4 Hepatitis C Virus (HCV): Implications for Antiviral Treatment Using Specifically Targeted Antiviral Therapy for HCVThe Journal of Infectious Diseases, 2009
- Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative BehaviorBiochemistry, 2009
- Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)Antimicrobial Agents and Chemotherapy, 2008
- Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase InhibitorsAntimicrobial Agents and Chemotherapy, 2008
- Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis CHepatology, 2007
- Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor TelaprevirGastroenterology, 2007
- Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patientsJournal of Medical Virology, 2005
- Sequences in the 5′ Nontranslated Region of Hepatitis C Virus Required for RNA ReplicationJournal of Virology, 2001